John F. Valentine,
MD
Associate Chief, Division of Gastroenterology
Languages Spoken: English
John F. Valentine, MD, is a Professor of Medicine at the University of Utah School of Medicine in the Division of Gastroenterology, Hepatology and Nutrition and specializes in ulcerative colitis and Crohn’s disease. His clinical interests and expertise are in inflammatory diseases of the intestinal tract that include inflammatory bowel disease (ulcerative colitis and Crohn’s disease) and celiac disease.
Dr. Valentine received his M.D. degree from the University of Texas Medical School at Houston in 1985. He received his training in Internal Medicine at the Medical College of Virginia-Virginia Commonwealth University Medical Center and his training in Gastroenterology at the University of Florida. While on faculty at the University of Florida, he rose to the position of Professor of Medicine, served as the Chief of the Gastroenterology Section at the Malcom Randal Veterans Administration Medical Center, and founded the Southeastern Center for Inflammatory Bowel Disease. He remains active with the Crohn’s and Colitis Foundation of America and has served a Co-Chair of the CCFA patient education committee and was a member of the editorial board for the journal Inflammatory Bowel Disease. Dr. Valentine is a Fellow in the American Gastroenterological Association and the director of the University of Utah Inflammatory Bowel Disease Center. Dr. Valentine has extensive experience with treating patients with inflammatory bowel disease and he is developing laboratory research and clinical trials in ulcerative colitis and Crohn’s disease in order to expand the understanding and treatment options for patients with these diseases.
Clinical Locations
801-213-9797
Gastroenterology, Area E
801-213-9797
Fax: (801) 585-2146
Gastroenterology Endoscopy Center
801-213-9797
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Gastroenterology |
| Board Certification | American Board of Internal Medicine American Board of Internal Medicine (Sub: Gastroenterology) |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.9/ 5
Care provider's explanation of condition/problem
4.8/ 5
Care provider's effort to include me in decisions
4.8/ 5
Wait time at clinic
4.5/ 5
Care provider's concern for questions & worries
4.8/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
March 21, 2022
UH HOSPITALS AND CLINICS
Understood my concerns and knew exactly what I was talking about
UofU Patient
March 03, 2022
SUGAR HOUSE HEALTH CENTER
Loved Dr. Valentine and associates!
UofU Patient
February 13, 2022
UH HOSPITALS AND CLINICS
Exceptional care
UofU Patient
December 09, 2021
SUGAR HOUSE HEALTH CENTER
There is never enough time to cover everything. Now my next appointment is in a year except for an emergency or with hands on treatment. He is a very knowledgeable physician and I appreciate his care and expert knowledge. Modern medicine, I guess.
UofU Patient
November 20, 2021
SUGAR HOUSE HEALTH CENTER
I love Dr Valentine!
UofU Patient
November 11, 2021
SUGAR HOUSE HEALTH CENTER
DrValentine is super
UofU Patient
November 10, 2021
UH HOSPITALS AND CLINICS
It is apparent that Dr. Valentine is a thoughtful and caring physician. I appreciated his willingness to answer my questions and make a plan that I was comfortable with.
UofU Patient
June 28, 2021
SUGAR HOUSE HEALTH CENTER
Dr. Valentine is exceptional. I appreciate his assertiveness.
UofU Patient
June 20, 2021
UH HOSPITALS AND CLINICS
my meeting was very thorough with full explanations and resources. my comments were listened to and responded to clearly
UofU Patient
June 01, 2021
UH HOSPITALS AND CLINICS
very satisfied
UofU Patient
May 16, 2021
UH HOSPITALS AND CLINICS
Dr. Valentine has shared more knowledge and understanding of my condition then any other DR. or specialist has been able to in the last 7 years. I have already been recommending U of U medical to anybody that will listen!
UofU Patient
May 15, 2021
SUGAR HOUSE HEALTH CENTER
Dr. Valentine is wonderful.
UofU Patient
May 02, 2021
UH HOSPITALS AND CLINICS
Dr.Valentine is truly professional. but show a high degree of caring in his professional interactions.
UofU Patient
April 02, 2021
SUGAR HOUSE HEALTH CENTER
Dr. Valentine is is excellent in his approach to my healthcare.
UofU Patient
March 15, 2021
UH HOSPITALS AND CLINICS
Dr. Valentine had someone he was mentoring talk to me. She asked good questions and was specific abt my situation. Dr. Valentine was in the background but actively participating, coaching her as needed. I had a question abt an over the counter medicine that I had started taking which was related to my condition and asked his advice abt it's efficacy. Dr. Valentine gave his opinion which was very helpful!
UofU Patient
March 08, 2021
SUGAR HOUSE HEALTH CENTER
Dr. Valentine is amazing. He displays genuine concern for my health and wellbeing.
UofU Patient
February 14, 2021
UH HOSPITALS AND CLINICS
excellent care
UofU Patient
February 09, 2021
UH HOSPITALS AND CLINICS
Dr Valentine is excellent -Would highly recommend
UofU Patient
February 07, 2021
UH HOSPITALS AND CLINICS
It was all well done.
UofU Patient
January 17, 2021
UH HOSPITALS AND CLINICS
Always very professional
UofU Patient
January 14, 2021
UH HOSPITALS AND CLINICS
If there is a little bit more explanation about my situation will be perfect.
UofU Patient
December 15, 2020
UH HOSPITALS AND CLINICS
Dr. Valentine is exceptional. I have been impressed with his care and concern and overall treatment plan progression for my diagnosis.
UofU Patient
October 31, 2020
SUGAR HOUSE HEALTH CENTER
Have already recommended
UofU Patient
September 10, 2020
SUGAR HOUSE HEALTH CENTER
good experience
UofU Patient
September 02, 2020
UH HOSPITALS AND CLINICS
Dr. Valentine is great. He listened to my questions and answered them thoroughly.
UofU Patient
August 02, 2020
SUGAR HOUSE HEALTH CENTER
I am a physician myself, Dr. Valentine is an ideal physician in all ways
UofU Patient
July 24, 2020
UH HOSPITALS AND CLINICS
the virtual visit was super easy. I was contacted well ahead of time that it would be virtual
UofU Patient
July 03, 2020
UH HOSPITALS AND CLINICS
I think he is very professional because he and his assistant asked a lot of questions and he knew every detail he needs to know about me. Literally, he did not show enough concern and give enough explanation, but I understood and appreciated what he has done. I hope every doctor can give patients an overall evaluation after interview and tell them what their current situation are, what they should do after interview, and why the proposed treatments are best for them.
John F. Valentine, MD, is a Professor of Medicine at the University of Utah School of Medicine in the Division of Gastroenterology, Hepatology and Nutrition and specializes in ulcerative colitis and Crohn’s disease. His clinical interests and expertise are in inflammatory diseases of the intestinal tract that include inflammatory bowel disease (ulcerative colitis and Crohn’s disease) and celiac disease.
Dr. Valentine received his M.D. degree from the University of Texas Medical School at Houston in 1985. He received his training in Internal Medicine at the Medical College of Virginia-Virginia Commonwealth University Medical Center and his training in Gastroenterology at the University of Florida. While on faculty at the University of Florida, he rose to the position of Professor of Medicine, served as the Chief of the Gastroenterology Section at the Malcom Randal Veterans Administration Medical Center, and founded the Southeastern Center for Inflammatory Bowel Disease. He remains active with the Crohn’s and Colitis Foundation of America and has served a Co-Chair of the CCFA patient education committee and was a member of the editorial board for the journal Inflammatory Bowel Disease. Dr. Valentine is a Fellow in the American Gastroenterological Association and the director of the University of Utah Inflammatory Bowel Disease Center. Dr. Valentine has extensive experience with treating patients with inflammatory bowel disease and he is developing laboratory research and clinical trials in ulcerative colitis and Crohn’s disease in order to expand the understanding and treatment options for patients with these diseases.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Gastroenterology |
| Board Certification | American Board of Internal Medicine American Board of Internal Medicine (Sub: Gastroenterology) |
Research Interests
- Crohn Disease
- Colitis, Ulcerative
- Intestinal Inflammation
- Epithelial Cells
- Translational Research
- Clinical Trials
Education History
| Fellowship | University of Florida College of Medicine Gastroenterology Fellow, 1991 |
| Internship/Residency | Medical College of Virginia Internal Medicine Intern/Resident, 1988 |
| Professional Medical | University of Texas Medical School at Houston Medicine M.D., 1985 |
| Undergraduate | University of Texas at Arlington Microbiology B.S., 1981 |
Selected Publications - Journal Articles
Journal Article
- Papamichael K, Jairath V, Zou G, Cohen B, Ritter T, Sands B, Siegel C, Valentine J, Smith M, Vande Casteele N, Dubinsky M, Cheifetz A (2022). Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ Open, 12(4), e057656.
- Tse CS, Van Citters AD, Ricci B, Freundlich NZ, Lee M, Shah SA, Melmed GY, Siegel CA, van Deen WK, IBD Qorus (2021). Identifying and Predicting the Goals and Concerns Prioritised by Individuals with Inflammatory Bowel Disease. J Crohns Colitis, 16(3), 379-388.
- Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ, HICKORY Study Group (2021). Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol, 7(2), 128-140.
- Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, Mishkin DS, Arrisi P, Scalori A, Oh YS, Tole S, Chai A, Chamberlain-James K, Lacey S, McBride J, Pans J, HIBISCUS Study Group (2021). Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol, 7(1), 17-27.
- Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG, LAUREL Study Group (2021). Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol, 7(1), 28-37.
- Ost KS, OMeara TR, Stephens WZ, Chiaro T, Zhou H, Penman J, Bell R, Catanzaro JR, Song D, Singh S, Call DH, Hwang-Wong E, Hanson KE, Valentine JF, Christensen KA, OConnell RM, Cormack B, Ibrahim AS, Palm NW, Noble SM, Round JL (2021). Adaptive immunity induces mutualism between commensal eukaryotes. Nature, 596(7870), 114-118.
- Lewis JD, Sandler R, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF, Hanson J, Suskind D, Meyer A, Compher CW, Bewtra M, Saxena A, Dobes A, Cohen B, Flynn AD, Fischer M, Saha S, Swaminath A, Yacyshyn B, Scherl E, Horst S, Curtis JR, Braly K, Nessel L, McCauley M, McKeever L, Herfarth H, DINE-CD Study Group (2021). A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults with Crohn's Disease. Gastroenterology, 161, 837-852.e9.
- Somineni HK, Nagpal S, Venkateswaran S, Cutler DJ, Okou DT, Haritunians T, Simpson CL, Begum F, Datta LW, Quiros AJ, Seminerio J, Mengesha E, Alexander JS, Baldassano RN, Dudley-Brown S, Cross RK, Dassopoulos T, Denson LA, Dhere TA, Iskandar H, Dryden GW, Hou JK, Hussain SZ, Hyams JS, Isaacs KL, Kader H, Kappelman MD, Katz J, Kellermayer R, Kuemmerle JF, Lazarev M, Li E, Mannon P, Moulton DE, Newberry RD, Patel AS, Pekow J, Saeed SA, Valentine JF, Wang MH, McCauley JL, Abreu MT, Jester T, Molle-Rios Z, Palle S, Scherl EJ, Kwon J, Rioux JD, Duerr RH, Silverberg MS, Zwick ME, Stevens C, Daly MJ, Cho JH, Gibson G, McGovern DPB, Brant SR, Kugathasan S (2021). Whole-genome sequencing of African Americans implicates differential genetic architecture in inflammatory bowel disease. Am J Hum Genet, 108(3), 431-445.
- Samadder NJ, Valentine JF, Guthery S, Singh H, Bernstein CN, Leighton JA, Wan Y, Wong J, Boucher K, Pappas L, Rowe K, Burt RW, Curtin K, Smith KR (2018). Family History Associates With Increased Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol, 17(9), 1807-1813.e1.
- Gogokhia L, Buhrke K, Bell R, Hoffman B, Brown DG, Hanke-Gogokhia C, Ajami NJ, Wong MC, Ghazaryan A, Valentine JF, Porter N, Martens E, OConnell R, Jacob V, Scherl E, Crawford C, Stephens WZ, Casjens SR, Longman RS, Round JL (2018). Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis. Cell Host Microbe, 25(2), 285-299.e8.
- Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PDR, Isaacs KL, Jackson S, Osterman MT, Anton K, Ivanova A, Long MD, Martin C, Sandler RS, Abraham B, Cross RK, Dryden G, Fischer M, Harlan W, Levy C, McCabe R, Polyak S, Saha S, Williams E, Yajnik V, Serrano J, Sands BE, Lewis JD, Clinical Research Alliance of the Crohns and Colitis Foundation (2018). Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology, 155(4), 1098-1108.e9.
- Johnson J, Affolter K, Boynton K, Chen X, Valentine J, Peterson K (2017). CMV Disease in IBD: Comparison of Diagnostic Tests and Correlation with Disease Outcome. Inflamm Bowel Dis, 24(7), 1539-1546.
- Brant SR, Okou DT, Simpson CL, Cutler DJ, Haritunians T, Bradfield JP, Chopra P, Prince J, Begum F, Kumar A, Huang C, Venkateswaran S, Datta LW, Wei Z, Thomas K, Herrinton LJ, Klapproth JA, Quiros AJ, Seminerio J, Liu Z, Alexander JS, Baldassano RN, Dudley-Brown S, Cross RK, Dassopoulos T, Denson LA, Dhere TA, Dryden GW, Hanson JS, Hou JK, Hussain SZ, Hyams JS, Isaacs KL, Kader H, Kappelman MD, Katz J, Kellermayer R, Kirschner BS, Kuemmerle JF, Kwon JH, Lazarev M, Li E, Mack D, Mannon P, Moulton DE, Newberry RD, Osuntokun BO, Patel AS, Saeed SA, Targan SR, Valentine JF, Wang MH, Zonca M, Rioux JD, Duerr RH, Silverberg MS, Cho JH, Hakonarson H, Zwick ME, McGovern DP, Kugathasan S (2017). Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. Gastroenterology, 152(1), 206-217.e2.
- Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S, Chopra P, Alexander JS, Baldassano RN, Cross RK, Dassopoulos T, Dhere TA, Duerr RH, Hanson JS, Hou JK, Hussain SZ, Isaacs KL, Kachelries KE, Kader H, Kappelman MD, Katz J, Kellermayer R, Kirschner BS, Kuemmerle JF, Kumar A, Kwon JH, Lazarev M, Mannon P, Moulton DE, Osuntokun BO, Patel A, Rioux JD, Rotter JI, Saeed S, Scherl EJ, Silverberg MS, Silverman A, Targan SR, Valentine JF, Wang MH, Simpson CL, Bridges SL, Kimberly RP, Rich SS, Cho JH, Rienzo AD, Kao LWH, McGovern DPB, Brant SR, Kugathasan S (2015). Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans. Gastroenterology, 149(6), 1575-1586.
- Runtsch MC, Hu R, Alexander M, Wallace J, Kagele D, Petersen C, Valentine JF, Welker NC, Bronner MP, Chen X, Smith DP, Ajami NJ, Petrosino JF, Round JL, OConnell RM (2015). MicroRNA-146a constrains multiple parameters of intestinal immunity and increases susceptibility to DSS colitis. Oncotarget, 6(30), 28556-72.
- Melmed GY, Pandak WM, Casey K, Abraham B, Valentine J, Schwartz D, Awais D, Bassan I, Lichtiger S, Sands B, Hanauer S, Richards R, Oikonomou I, Parekh N, Targan S, Johnson K, Hariri R, Fischkoff S (2015). Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study. Inflamm Bowel Dis, 21(8), 1809-16.
- Koboziev I, Jones-Hall Y, Valentine JF, Webb CR, Furr KL, Grisham MB (2015). Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases. Inflamm Bowel Dis, 21(7), 1652-73.
- Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R (2015). Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis, 21(6), 1329-40.
- Xia CQ, Peng R, Chernatynskaya AV, Yuan L, Carter C, Valentine J, Sobel E, Atkinson MA, Clare-Salzler MJ (2014). Increased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production. J Immunol, 193(3), 1024-34.
- Faubion WA Jr, Fletcher JG, OByrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME (2013). EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol, 108(12), 1891-900.
- Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT (2013). Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol, 11(3), 286-92; quiz e24.
- Ukhanova M, Culpepper T, Baer D, Gordon D, Kanahori S, Valentine J, Neu J, Sun Y, Wang X, Mai V (2012). Gut microbiota correlates with energy gain from dietary fiber and appears to be associated with acute and chronic intestinal diseases. Clin Microbiol Infect, 18, 62-66.
- Wang MH, Okazaki T, Kugathasan S, Cho JH, Isaacs KL, Lewis JD, Smoot DT, Valentine JF, Kader HA, Ford JG, Harris ML, Oliva-Hemker M, Cuffari C, Torbenson MS, Duerr RH, Silverberg MS, Rioux JD, Taylor KD, Nguyen GC, Wu Y, Datta LW, Hooker S, Dassopoulos T, Kittles RA, Kao LW, Brant SR (2012). Contribution of higher risk genes and European admixture to Crohn's disease in African Americans. Inflamm Bowel Dis, 18(12), 2277-87.
- Davis MK, Valentine JF, Weinstein DA, Polyak S (2010). Antibodies to CBir1 are associated with glycogen storage disease type Ib. J Pediatr Gastroenterol Nutr, 51(1), 14-8.
- Ahmadi A, Li Q, Muller K, Collins D, Valentine JF, Drane W, Polyak S (2010). Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography enterography in active Crohn's disease. Inflamm Bowel Dis, 16(6), 974-81.
- Dassopoulos T, Nguyen GC, Talor MV, Datta LW, Isaacs KL, Lewis JD, Gold MS, Valentine JF, Smoot DT, Harris ML, Oliva-Hemker M, Bayless TM, Burek CL, Brant SR (2010). NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African Americans. Am J Gastroenterol, 105(2), 378-86.
- Valentine JF, Fedorak RN, Feagan B, Fredlund P, Schmitt R, Ni P, Humphries TJ (2009). Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut, 58(10), 1354-62.
- Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ (2005). Sargramostim for active Crohn's disease. N Engl J Med, 352(21), 2193-201.
- Naser SA, Ghobrial G, Romero C, Valentine JF (2004). Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet, 364(9439), 1039-44.
- Valentine JF (2001). Mesalamine induces manganese superoxide dismutase in rat intestinal epithelial cell lines and in vivo. Am J Physiol Gastrointest Liver Physiol, 281(4), G1044-50.
Abstract
- Mach A, Glover S, Valentine JF (2012). GM-CSF and IL23 Protect the Intestinal Epithelial Barrier from Disruption by IFN Treatment. [Abstract]. DDW- Sandiego, CA.
- Gaidos JKJ, Sultan S, Dahl W, Valentine JF (Dec 9-12, 2010). Vitamin D Deficiency in Inflammatory Bowel Disease. Advances in IBD Annual CCFA Meeting. Ft. Lauderdale, FL. [Abstract].
Patent
- Valentine JF (2004). Manganese superoxide dismutase regulatory elements and the uses thereof. U.S. Patent No. 6,800,458. Washington, D.C.:U.S. Patent and Trademark Office.